Evidence map›Paper›PMID 36279094›Full record

ArticleActa neurologica Belgica2023

COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.

Stojan Peric, Milos Rankovic, Ivo Bozovic, Vanja Radosavljevic, Ivan Marjanovic, Ivana Basta, Dragana Lavrnic

Open access · bronzeAbstract read
In one paragraph

Article in Acta neurologica Belgica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Myotonic dystrophy type 1 in the COVID-19 era.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Stojan PericUniversity of Belgrade-Faculty of Medicine, University Clinical Center of Serbia-Neurology Clinic, Belgrade, Serbia.
Milos RankovicUniversity Clinical Centre of Serbia - Neurology Clinic, Dr Subotic Street 6, 11000, Belgrade, Serbia.
Ivo BozovicUniversity Clinical Centre of Serbia - Neurology Clinic, Dr Subotic Street 6, 11000, Belgrade, Serbia. ivo.bozovic20@gmail.com.ORCID http://orcid.org/0000-0002-6623-0779
Vanja RadosavljevicUniversity Clinical Centre of Serbia - Neurology Clinic, Dr Subotic Street 6, 11000, Belgrade, Serbia.
Ivan MarjanovicPrivate Consultant in Neurology, Milan, Italy.
Ivana BastaUniversity of Belgrade-Faculty of Medicine, University Clinical Center of Serbia-Neurology Clinic, Belgrade, Serbia.
Dragana LavrnicUniversity of Belgrade-Faculty of Medicine, University Clinical Center of Serbia-Neurology Clinic, Belgrade, Serbia.
University of Belgrade · RSUniverzitetski Klinički Centar Srbije · RS

Funding

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja 175083
6 · The paper itself

Abstract

introductionMyasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction which is typically presented with muscle weakness and excessive fatigability. Majority of MG patients require long-term immune suppression. Our aim was to analyze the frequency and severity of COVID-19 infection in MG patients, as well as the frequency of vaccinated MG patients against SARS-CoV-2.

methodsWe included 125 MG patients from the central Belgrade municipalities-60% females, age at MG onset 50.1 ± 19.7 years, age at testing 61.7 ± 16.8 years, anti-acetylcholine receptor (anti-AChR) positive 78% and muscle specific tyrosine kinase (MuSK) positive 8.6%.

resultsOne-third of our MG patients had a COVID-19 infection and they were younger compared to those without verified COVID-19. Severe COVID-19 infection was registered in 28% of MG patients, mostly in elder subjects with comorbidities such as cardiac diseases and malignancies. MG worsening was noted in 21% of patients during/after COVID-19 and 42% had COVID-19 sequelae. Majority of MG patients were vaccinated against SARS-CoV-2 (almost 70%). Vaccination was more common among MG patients with diabetes and in those with a milder form of MG. The most common types of vaccines were Sinopharm (42%) and Pfizer-BioNTech (25.6%). Adverse events were observed in 36% of vaccinated patients, with flu-like symptoms (77%) and local reactions (13%) being the most common ones. MG worsening was noticed in 5 (5.8%) patients after vaccination.

conclusionCOVID-19 has placed a significant new burden for MG patients. Elder MG patients and patients with comorbidities are in higher risk of having adverse outcome following SARS-CoV-2 infection. Percentage of vaccinated MG patients was higher than in general Serbian population.

Indexed as

COVID-19Myasthenia GravisAgedAutoantibodiesFemaleHumansMaleSARS-CoV-2VaccinationAutoantibodiesCOVID-19 infectionMyasthenia gravisSARS-CoV-2Vaccination

Identifiers

PMID36279094
PMCPMC9589734
OpenAlexW4307297974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.